Standout Papers

Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk 2024 202683
  1. Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk (2024)
    Brian A. Bergmark, Nicholas Marston et al. New England Journal of Medicine
  2. Lipoprotein(a), C-Reactive Protein, and Cardiovascular Risk in Primary and Secondary Prevention Populations (2024)
    Aeron Small, Giorgio Melloni et al. JAMA Cardiology

Immediate Impact

4 from Science/Nature 64 standout
Sub-graph 1 of 21

Citing Papers

Atrial fibrillation burden: a new outcome predictor and therapeutic target
2024 Standout
Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk
2024 Standout
5 intermediate papers

Works of Nicholas Marston being referenced

Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk
2024 Standout
Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score
2019
and 2 more

Author Peers

Author Last Decade Papers Cites
Nicholas Marston 490 516 279 45 1.0k
Mahmoud Barbir 450 855 323 50 1.2k
Anandita Agarwala 416 545 347 58 1.1k
Heinz Drexel 429 248 225 51 1.1k
Estíbaliz Jarauta 360 568 276 64 1.1k
Tsuyoshi Nozue 265 653 279 72 1.1k
G. Rosenhamer 605 536 385 38 1.2k
Athanasios G. Kontopoulos 609 905 455 26 1.4k
Alexander Vonbank 347 381 264 101 1.2k
J.J.P. Kastelein 315 817 416 30 1.2k
Brian T. Steffen 376 589 305 46 1.1k

All Works

Loading papers...

Rankless by CCL
2026